Skip to content
PubMed This is a summary of 10 peer-reviewed journal articles Updated
Nephrology

Understanding FRTS3: Biology and Genetics

At a Glance

FRTS3 is a rare inherited kidney disorder caused by a disease-causing change in the EHHADH gene. It disrupts the proximal tubules’ ability to reclaim substances using cellular energy, leading to urinary loss of glucose, phosphate, or other nutrients and a wide range of symptoms.

Fanconi renotubular syndrome 3 (FRTS3) is an exceptionally rare genetic condition that affects the kidneys’ ability to reabsorb essential nutrients and minerals [1]. Unlike more common kidney diseases that affect the organ’s “filters,” FRTS3 targets the specialized transport system in the proximal tubule—the part of the kidney responsible for reclaiming vital substances before they are lost in the urine [2].

The Rarity of FRTS3

This condition is considered extremely rare. Since it was first identified, only a small number of families worldwide have been reported in the medical literature [1][3]. Because so few people have been diagnosed, our understanding of the disease continues to grow with every new case identified and shared by researchers [1].

The Role of the Proximal Tubule

To understand FRTS3, it helps to think of the kidney as a high-volume recycling center. After the blood is filtered, the resulting fluid contains many things the body still needs, such as glucose (sugar), phosphate, amino acids (the building blocks of protein), and bicarbonate [4].

The proximal tubule is the first and most active part of the kidney’s recycling line [2]. It is lined with cells that use massive amounts of energy to pump these substances back into the bloodstream [5]. In FRTS3, this pumping system fails because the cells run out of the “fuel” needed to operate the pumps [6].

How the Genetic Variant Causes the Disease

The condition is caused by a pathogenic variant in the EHHADH gene (most commonly reported as the p.Glu3Lys or p.E3K variant) [3][7]. Genes are the instructions for building proteins, and the EHHADH gene normally provides instructions for an enzyme that works inside the peroxisome—a part of the cell that breaks down fats [8].

For the most commonly reported variant, research proposes that the mutation acts like a “wrong address” label on the protein. Instead of going to the peroxisome, experimental models suggest the protein is mislocalized (sent to the wrong place) to the mitochondria [6][3]. The mitochondria are the “power plants” of the cell, responsible for generating energy in the form of ATP [9].

When the mutant EHHADH protein enters the mitochondria, it interferes with their ability to produce energy [6]. Because the proximal tubule cells have some of the highest energy demands in the entire body, they are the first to fail when the power plants are disrupted [5]. Without enough ATP, the cells cannot pull nutrients back into the body, and those nutrients are “wasted” into the urine [3][7]. It is currently uncertain if this exact mechanism applies to every pathogenic EHHADH variant.

Understanding Inheritance

FRTS3 is an autosomal dominant condition [1]. This means:

  • Autosomal: The gene is located on one of the numbered chromosomes, so it affects males and females equally.
  • Dominant: You only need one copy of the variant (from one parent) to have the condition genetically.

If a parent has the variant, there is a 50% chance they will pass the variant on to each child. However, researchers have observed variable expressivity, meaning that even within the same family, some people with the variant may have severe symptoms, while others have very mild symptoms or no symptoms at all [1][3].

A Spectrum of Symptoms

Because of this variability, FRTS3 is viewed as a spectrum rather than a single predictable set of symptoms:

  • Individuals with the Variant Who Are Currently Asymptomatic: Because it is autosomal dominant, a person with the variant has the genetic condition even if they have no physical symptoms [1]. They may only have “silent” lab abnormalities like glucosuria (sugar in the urine) or mild proteinuria (protein in the urine) during a routine check-up.
  • Full Fanconi Syndrome: Others develop “generalized” Fanconi syndrome, where they lose many different substances. This can lead to complications like rickets (bone weakening) due to the loss of phosphate [1][10].
  • Kidney Function: While many patients maintain relatively stable kidney function for a long time, some cases of earlier kidney impairment have been reported [1].

Research is ongoing to determine why the disease affects people so differently, even when they carry the exact same genetic variant.

Common questions in this guide

What is FRTS3?
FRTS3, or Fanconi renotubular syndrome 3, is an exceptionally rare inherited kidney condition caused by a disease-causing variant in the EHHADH gene. It affects the proximal tubules, which normally return glucose, phosphate, amino acids, and bicarbonate to the bloodstream after the kidneys filter the blood.
How can an EHHADH variant cause FRTS3?
The most commonly reported EHHADH variant, p.Glu3Lys (p.E3K), may send the altered protein to mitochondria instead of peroxisomes. Experimental models suggest this could interfere with the cell’s energy production, but researchers do not know whether the same mechanism applies to every EHHADH variant.
How is FRTS3 inherited?
FRTS3 is autosomal dominant, so one altered copy of the EHHADH gene can cause the condition. If a parent carries the variant, each child has a 50% chance of inheriting it, although symptoms can differ greatly among relatives.
What symptoms or urine findings can FRTS3 cause?
Some people have no noticeable symptoms and only show glucose or small amounts of protein in the urine. Others develop generalized Fanconi syndrome, with losses of several substances including phosphate that can contribute to rickets. Kidney function may remain stable for a long time, although earlier impairment has been reported.
Should relatives be tested for FRTS3?
Because FRTS3 is autosomal dominant, a person with the variant has a 50% chance of passing it to each child. A nephrologist or genetic counselor can review the family history and discuss targeted testing for relatives, including those who do not have symptoms.

Get notified when new evidence is published on Fanconi renotubular syndrome 3.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (10)
  1. 1

    A puzzling renal Fanconi syndrome.

    Haydock L, Hureaux M, Hoffmann M, et al.

    Clinical kidney journal 2025; (18(8)):sfae408 doi:10.1093/ckj/sfae408.

    PMID: 40800210
  2. 2

    Proximal renal tubular acidosis with and without Fanconi syndrome.

    Kashoor I, Batlle D

    Kidney research and clinical practice 2019; (38(3)):267-281 doi:10.23876/j.krcp.19.056.

    PMID: 31474092
  3. 3

    The recurrent p.Glu3Lys variant in EHHADH is responsible for Fanconi syndrome with early liver dysfunction and mitochondrial abnormalities.

    Rollier P, Cospain A, Barth M, et al.

    Molecular genetics and metabolism reports 2025; (43()):101214 doi:10.1016/j.ymgmr.2025.101214.

    PMID: 40242153
  4. 4

    Drug toxicity in the proximal tubule: new models, methods and mechanisms.

    Hall AM, Trepiccione F, Unwin RJ

    Pediatric nephrology (Berlin, Germany) 2022; (37(5)):973-982 doi:10.1007/s00467-021-05121-9.

    PMID: 34050397
  5. 5

    Distinct Mitochondrial Pathologies Caused by Mutations of the Proximal Tubular Enzymes EHHADH and GATM.

    Forst AL, Reichold M, Kleta R, Warth R

    Frontiers in physiology 2021; (12()):715485 doi:10.3389/fphys.2021.715485.

    PMID: 34349672
  6. 6

    Renal Fanconi Syndrome Is Caused by a Mistargeting-Based Mitochondriopathy.

    Assmann N, Dettmer K, Simbuerger JMB, et al.

    Cell reports 2016; (15(7)):1423-1429 doi:10.1016/j.celrep.2016.04.037.

    PMID: 27160910
  7. 7

    Unveiling long-standing low-molecular-weight proteinuria: A proximal tubular mitochondrial enzyme impairment caused by EHHADH mutation.

    Tanaka H, Imasawa T, Tsugawa K, et al.

    Pediatric nephrology (Berlin, Germany) 2026; (41(3)):675-678 doi:10.1007/s00467-025-07020-9.

    PMID: 41117969
  8. 8

    Enoyl-CoA hydratase/3-hydroxyacyl CoA dehydrogenase is essential for the production of DHA in zebrafish.

    Yang G, Sun S, He J, et al.

    Journal of lipid research 2023; (64(3)):100326 doi:10.1016/j.jlr.2022.100326.

    PMID: 36592657
  9. 9

    Crystal structure of human mitochondrial trifunctional protein, a fatty acid β-oxidation metabolon.

    Xia C, Fu Z, Battaile KP, Kim JP

    Proceedings of the National Academy of Sciences of the United States of America 2019; (116(13)):6069-6074 doi:10.1073/pnas.1816317116.

    PMID: 30850536
  10. 10

    [GENETIC DISORDERS OF RENAL PHOSPHATE HANDLING].

    Magen D

    Harefuah 2017; (156(10)):654-658.

    PMID: 29072386

This page is for informational purposes only and does not constitute medical advice about FRTS3. A nephrologist or genetics professional should interpret genetic results and recommend monitoring for your family.